|  
      
         
      
        
     | 
      | 
     
         
       
      
       
        Bibliography- 
          Stephen 
          G. Swisher, M.D.  
         
        Published 
          and accepted invited journal articles 
        
          - Swisher, S.G., 
            Roth, J.A., and Putnam, J.B., Jr. Diagnosis and management of benign 
            esophageal tumors. Cancer 
            Bull., 47:396-401, 1995.
 
          - Roth, J.A., Swisher, 
            S.G., Bouvet, M., and Merritt, J.A. p53 gene replacement therapy 
            in lung cancer. Adv. Oncol., 14:2-7, 1998.
 
          - Swisher, S.G., 
            and Roth, J.A. Gene therapy for human lung cancers. Sur. 
            Oncol. Clin. N. Am., 7:603-616, 1998. 
 
          - Swisher, S.G. 
            Commentary on "Viral Oncolytic Treatment of Cancer". Clin. Lung Cancer, 
            1:56, 1999.
 
          - Roth, J.A., Swisher, 
            S.G., and Meyn, R.E. p53 tumor suppressor gene therapy for cancer. 
            Oncology, 
            13:148-154, 1999.
 
          - Pataer, A., Fang, 
            B., Roth, J.A., and Swisher, S.G. Adenoviral bak overexpression 
            mediates caspase-dependent tumor killing. Cancer 
            Res. Alert, 2:17-19, 2000.
 
          - Fine, A., Janssen-Heinninger,Y., 
            Soultanakis,R.P., Swisher, S.G., and Uhal, B.D. Apoptosis in lung 
            pathophysiology. Am. 
            J. Physiol. Lung Cell Mol. Physiol., 279:L423-L427, 2000.
 
          - Swisher, S.G., 
            Pisters, P.W., Komaki, R., Lahoti, S., and Ajani, J.A. GE junction 
            adenocarcinoma. Curr. Treat. Options Oncol., 1:387-398, 2000. 
 
          - Swisher, S.G. 
            Inhibition of nuclear factor kB chemosensitizes non-small cell lung 
            cancer through cytochrome c release and caspase activation. J. 
            Thorac. Cardiovasc. Surg., 123:317, 2002. Commentary.
 
          - Swisher, S.G. 
            Apo2L/TRAIL-induced apoptosis in NSCLC cell lines is enhanced by chemotherapeutic 
            agents but not correlated to the expression level of c-FLIP. J. 
            Thorac. Cardiovasc. Surg., 124:174, 2002. 
 
          - Swisher, S.G., 
            Roth, J.A., and Carbone, D.P. Genetic and immunologic therapies for 
            lung cancer. 
            Semin. Oncol., 29:95-101, 2002. 
 
          - Swisher, S.G., 
            and Roth, J.A. p53 Gene therapy for lung cancer. Curr. Oncol. Rep., 
            4(4):334-340, 2002.
 
          - Nemunaitis, J., 
            Swisher, S.G., Timmons, T., Connors, D., Mack, M., Doerksen, 
            L., Weill, D., Wait, J., Lawrence, D.D., Kemp, B.L., Fossella, F., 
            Glisson, B.S., Hong, W.K., Khuri, F.R., Kurie, J.M., Lee, J.J., Lee, 
            J.S., Nguyen, D.M., Nesbitt, J.C., Perez-Soler, R., Pisters, K.M.W., 
            Putnam, J.B., Jr., Richli, W.R., Shin, D.M., Walsh, G.L., Merritt, 
            J., and Roth, J.A. Adenovirus-mediated p53 gene transfer in sequence 
            with cisplatin to tumors of patients with non-small cell lung cancer: 
            Author Update. J. Clin. Oncol., in press, 2002.
 
          - Swisher, S.G., 
            and Roth, J.A. Clinical Update: of Ad-p53 Gene Therapy for Lung Cancer. 
            Surg. Oncol. Clin. N. Am., in press, 2002.
 
         
        Back 
          to Top 
       
       
        
        
         
     |